PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.97%
Revenue growth at 50-75% of CRON.TO's 26.40%. Martin Whitman would worry about competitiveness or product relevance.
-9.53%
Negative gross profit growth while CRON.TO is at 366.16%. Joel Greenblatt would examine cost competitiveness or demand decline.
-37.46%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-37.46%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
111.86%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
116.82%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
116.82%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
68.21%
Share count expansion well above CRON.TO's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
68.21%
Slight or no buyback while CRON.TO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
9996.05%
Positive OCF growth while CRON.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
105.91%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
759.81%
5Y revenue/share CAGR under 50% of CRON.TO's 2625.27%. Michael Burry would suspect a significant competitive gap or product weakness.
558.89%
3Y revenue/share CAGR above 1.5x CRON.TO's 308.39%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
1314.74%
Positive long-term OCF/share growth while CRON.TO is negative. John Neff would see a structural advantage in sustained cash generation.
272.75%
Positive OCF/share growth while CRON.TO is negative. John Neff might see a comparative advantage in operational cash viability.
153.74%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
1568.31%
Positive 10Y CAGR while CRON.TO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
378.70%
Positive 5Y CAGR while CRON.TO is negative. John Neff might view this as a strong mid-term relative advantage.
445.35%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
10037.12%
10Y equity/share CAGR above 1.5x CRON.TO's 1714.39%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
2200.76%
5Y equity/share CAGR 1.25-1.5x CRON.TO's 1694.65%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
109.26%
Below 50% of CRON.TO's 406.18%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.83%
AR growth is negative/stable vs. CRON.TO's 79.16%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-4.14%
Inventory is declining while CRON.TO stands at 3.25%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
173.68%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
115.95%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
28.79%
We have some new debt while CRON.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
188.72%
R&D growth drastically higher vs. CRON.TO's 1.30%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-20.02%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.